Policy Roadmap for Medicines Manufacturing Leadership

Call for tenders SANTE/2020/C3/29 for the supply of medicinal products used for intensive care patients subject to the novel coronavirus (COVID-19) disease – policy and technical concerns

Preparing for a potential second COVID-19 wave. Joint statement by Medicines for Europe and EFPIA with Kearney

LESSONS LEARNED FROM COVID-19 – POLICY PAPER

Questions and answers on regulatory expectations for medicinal products for human use during the COVID-19 pandemic

Position Paper. Incentives Review The Orphan and Paediatric Incentives

Why is Now the Right Time to Modernise the Eu Variations System?

AMR Industry Alliance 2020 Progress Report

Biosimilars in the EU – Information guide for healthcare professionals – now available in 23 languages

  • English

    (PDF/1.85 MB)

    Bulgarian

    (PDF/1.82 MB)

  • Croatian

    (PDF/1.81 MB)

  • Czech

    (PDF/1.86 MB)

  • Danish

    (PDF/1.84 MB)

  • Dutch

    (PDF/1.83 MB)

  • Estonian

    (PDF/656.54 KB)

  • Finnish

    (PDF/1.79 MB)

  • French

    (PDF/1.86 MB)

  • German

    (PDF/1.9 MB)

  • Greek

    (PDF/1.84 MB)

  • Hungarian

    (PDF/1.86 MB)

  • Italian

    (PDF/1.85 MB)

  • Latvian

    (PDF/1.8 MB)

  • Lithuanian

    (PDF/1.81 MB)

  • Maltese

    (PDF/710.75 KB)

  • Polish

    (PDF/1.87 MB)

  • Portuguese

    (PDF/1.85 MB)

  • Romanian

    (PDF/1.86 MB)

  • Slovak

    (PDF/1.86 MB)

  • Slovenian

    (PDF/1.86 MB)

  • Spanish

    (PDF/1.84 MB)

  • Swedish

    (PDF/1.84 MB)

Overarching recommendations for improved access to generic and biosimilar medicines in the hospital setting